Survival and cause of death in multiple sclerosis: a prospective population-based study

Abstract

These results confirm a continuing trend of premature death in patients with MS. Relying on data derived from death certificates will underestimate disease prevalence. Differences were identified between those dying from MS-related causes and those dying from other causes.

Autologous non-myeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: a phase I/II study

“…Short-term disease-related mortality from MS, equivalent to an EDSS of 10.0, is relatively uncommon. However, MS patients are 3 times more likely to die than the general population (27) and long-term disease-related mortality increases with increasing baseline EDSS (28). In one study with 20 years of follow-up, MS-related mortality was 14% for enrollment EDSS 0 to 3; 19% for enrollment EDSS 3.5 to 5.5; 36% for enrollment EDSS 6 to 7.5; and 62% for enrollment EDSS 8 to 9.5 (28).…”

Analysis of Diagnoses Associated with Multiple Sclerosis–Related In-Hospital Mortality Using the Premier Hospital Database

“…19 A t test at the P < .05 threshold of significance was used to analyze each conous research has shown high rates of death in this population, attributed to cardiovascular disease, infection, respiratory disease, and MS itself. [3][4][5][6]12,15,16 Interpretation of these findings is complicated by the different-and subjective-determinants of causes of death (eg, death certificates and registry data) used across studies or the length of time for the analysis, as many longitudinal studies have spanned decades, with medical advances over time confounding interpretation. 3,12,13,15,16 Studies examining large numbers of patients over a relatively short period using objective measures of mortality are, therefore, needed.…”

“…If the clinical presentation is benign, MS is unlikely to be recorded as a cause of death despite its potential contribution to mortality, although many studies have attributed more than 50% of deaths in this population to MS. [3][4][5][6]12,15,16 Patients also often have multiple comorbid conditions that may overshadow the effects of MS on survival outcomes. 5 In addition, only a few studies have focused on US-based cohorts, 7,13,17,18 and none have reported in-hospital mortality using objective disease classification codes.…”

Long-term immunomodulatory treatment and quality of life of patients with multiple sclerosis

“…Multiple sclerosis registry studies show an average survival time of MS patients ranging from 20 to 45 years from the onset of disease symptoms (Bronnum-Hansen et al, 2004, Sumelahti et al, 2010, Smestad et al, 2009, Wallin et al, 2000, Hirst et al, 2008, Leray et al, 2007. However, there is a significant negative impact on life expectancy due to MS, the survival disadvantage ranging from 7 to 14 years compared to the general population.…”